» Articles » PMID: 32799763

Gastric Cancer Heterogeneity and Clinical Outcomes

Overview
Date 2020 Aug 18
PMID 32799763
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Gastric adenocarcinoma is a highly aggressive disease with poor overall survival. The aggressive nature of this disease is in part due to the high intra and inter tumoral heterogeneity and also due to the late diagnosis at presentation. Once progression occurs, treatment is more difficult due to the adaptation of tumors, which acquires resistance to commonly used chemotherapeutics. In this report, using publicly available data sets and pathway analysis, we highlight the vast heterogeneity of gastric cancer by investigating genes found to be significantly perturbed. We found several upregulated genes in the diffuse gastric cancer subtypes share similarity to gastric cancer as a whole which can be explained by the increase in this subtype of gastric cancer throughout the world. We report significant downregulation of genes that are underrepresented within the literature, such as , , and , while other genes have not been explored within gastric cancer to the best of our knowledge such as , , , and . We identified gender to be another heterogeneous component of this disease and suggested targeted treatment strategies specific to this heterogeneity. In this study, we provide an in-depth exploration of the molecular landscape of gastric cancer in order to shed light onto novel areas of gastric cancer research and explore potential new therapeutic targets.

Citing Articles

Hypomethylation of isoform A correlates with transcriptional expression and is associated with poor survival in acute myeloid leukemia.

Wu D, Qiu H, Xu J, Lin J, Qian J Front Immunol. 2025; 16:1490330.

PMID: 40034691 PMC: 11873079. DOI: 10.3389/fimmu.2025.1490330.


Validity of the Global Leadership Initiative on Malnutrition criteria in East Asian patients with gastric cancer: a comprehensive narrative review.

Wang J, Liu B, Chen J Front Nutr. 2024; 11:1462487.

PMID: 39634550 PMC: 11614637. DOI: 10.3389/fnut.2024.1462487.


Representing ECM composition and EMT pathways in gastric cancer using a new metastatic gene signature.

Albano F, Russi S, Laurino S, Mazzone P, Di Paola G, Zoppoli P Front Cell Dev Biol. 2024; 12:1481818.

PMID: 39563861 PMC: 11573575. DOI: 10.3389/fcell.2024.1481818.


Stimulative piezoelectric nanofibrous scaffolds for enhanced small extracellular vesicle production in 3D cultures.

Johnston J, Jeon H, Choi Y, Kim G, Shi T, Khong C Biomater Sci. 2024; 12(22):5728-5741.

PMID: 39403853 PMC: 11474809. DOI: 10.1039/d4bm00504j.


Single-cell sequencing analysis revealed that WDR72 was a novel cancer stem cells related gene in gastric cancer.

Zheng L, Lu J, Kong D, Zhan Y Heliyon. 2024; 10(15):e35549.

PMID: 39170171 PMC: 11336769. DOI: 10.1016/j.heliyon.2024.e35549.


References
1.
Wang T, Xu Y, Hou P . Identifying novel biomarkers of gastric cancer through integration analysis of single nucleotide polymorphisms and gene expression profile. Int J Biol Markers. 2015; 30(3):e321-6. DOI: 10.5301/jbm.5000145. View

2.
Stojanovic J, Tognetto A, Tiziano D, Leoncini E, Posteraro B, Pastorino R . MicroRNAs expression profiles as diagnostic biomarkers of gastric cancer: a systematic literature review. Biomarkers. 2018; 24(2):110-119. DOI: 10.1080/1354750X.2018.1539765. View

3.
Dragovich T, McCoy S, Fenoglio-Preiser C, Wang J, Benedetti J, Baker A . Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol. 2006; 24(30):4922-7. DOI: 10.1200/JCO.2006.07.1316. View

4.
Fikree A, Chelimsky G, Collins H, Kovacic K, Aziz Q . Gastrointestinal involvement in the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017; 175(1):181-187. DOI: 10.1002/ajmg.c.31546. View

5.
Patti M, Schlottmann F . Gastroesophageal reflux disease: from heartburn to Barrett esophagus, and beyond. Updates Surg. 2018; 70(3):307. DOI: 10.1007/s13304-018-0587-4. View